triamcinolone acetonide has been researched along with 4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 2 (100.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Burns, TL; Rusin, LJ; Stawiski, MA; Voorhees, JJ; Weinstein, GD | 1 |
Black, AC; Sandquist, D; Williams, LR; Williams, TH | 1 |
1 trial(s) available for triamcinolone acetonide and 4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone
Article | Year |
---|---|
Ro 20-1724: an agent that significantly improves psoriatic lesions in double-blind clinical trials.
Topics: 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone; Adolescent; Adult; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Imidazoles; Male; Placebos; Psoriasis; Triamcinolone Acetonide | 1979 |
1 other study(ies) available for triamcinolone acetonide and 4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone
Article | Year |
---|---|
Glucocorticoids increase tyrosine hydroxylase activity in cultured murine neuroblastoma.
Topics: 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone; Androstenedione; Animals; Cells, Cultured; Cortodoxone; Cyclic AMP; Dexamethasone; Estradiol; Ethanol; Glucocorticoids; Mice; Neuroblastoma; Testosterone; Triamcinolone Acetonide; Tyrosine 3-Monooxygenase | 1981 |